Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation (Q34631315)

3 August 2017

Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation (English)

1 reference

3 August 2017

0 references

Lisa-Gaye Robinson

1

1 reference

3 August 2017

Joseph Hilinski

2

1 reference

3 August 2017

Fitzroy Graham

3

1 reference

3 August 2017

Leonard Hymes

4

1 reference

3 August 2017

Consuelo M Beck-Sague

5

1 reference

3 August 2017

Jason Hsia

6

1 reference

3 August 2017

Steven R Nesheim

7

1 reference

3 August 2017

1 April 2002

1 reference

Pediatric Transplantation

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

2

1 reference

3 August 2017

111-118

1 reference

Cytomegalovirus infections following renal transplantation--effects on antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study

3 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

Primary infections of Epstein-Barr virus, cytomegalovirus, and human herpesvirus-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

Brief report: parainfluenza virus type 3 infections: findings in Sydney and some observations on variations in seasonality world-wide

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Effect of antithymocyte globulin induction treatment on renal transplant outcome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

The use of Mycophenolate Mofetil (Cellcept) in renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Prospective cytomegalovirus surveillance in paediatric renal transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Cytomegalovirus prophylaxis in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Comparison of ganciclovir- and immune globulin-containing regimens in preventing cytomegalovirus infection in patients with renal transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Immunomodulation by viruses: the myxoma virus story

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

The human polyomavirus BK T antigen induces gene expression in human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

Transactivation of the human immunodeficiency virus promoter by human herpesvirus 6 (HHV-6) strains GS and Z-29 in primary human T lymphocytes and identification of transactivating HHV-6(GS) gene fragments

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01049.X

7 January 2021

10.1034/J.1399-3046.2002.01049.X

Identifiers

DOI

1 reference

3 August 2017

1 reference